Eastman Kodak Company's Molecular Imaging Systems unit today announced the availability of two new digital imaging systems for in vivo molecular imaging research in fields such as cancer, heart disease or drug discovery.
In vivo molecular imaging allows non-invasive measurement of biological processes within a living organism. In contrast to conventional diagnostic imaging that highlights conditions caused by disease, molecular imaging identifies molecular abnormalities that are the origin of disease at a very early stage, which can expedite the development of therapeutic pathways that could help cure that disease.
"Kodak's Image Station In-Vivo FX and F systems represent a significant milestone in our strategy to become a leader in molecular imaging," said Shahram Hejazi, General Manager of Kodak's Molecular Imaging Systems unit. "The availability of these innovative molecular imaging systems can significantly enhance research by enabling the visualization of very early disease states. Information obtained about disease origin can lead to development of effective therapeutics."
Both the KODAK Image Station In-Vivo F and FX systems, available immediately, feature Kodak's leading-edge digital image capture technology for highly sensitive optical imaging of biological processes at a molecular level. The In-Vivo FX system also includes a digital x-ray imaging module in addition to its optical imaging capability. The use of optical images with the digital x-ray images results in significant improvement in visualization of the area of interest. Both systems include KODAK Molecular Imaging software for additional quantitative analysis.